Stealth BioTherapeutics (NASDAQ:MITO) is set to release its earnings data before the market opens on Thursday, November 14th. Analysts expect Stealth BioTherapeutics to post earnings of ($0.04) per share for the quarter.
Stealth BioTherapeutics (NASDAQ:MITO) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. On average, analysts expect Stealth BioTherapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ:MITO traded up $0.32 on Tuesday, hitting $6.79. The company’s stock had a trading volume of 7,690 shares, compared to its average volume of 26,118. The company has a current ratio of 2.13, a quick ratio of 2.13 and a debt-to-equity ratio of 0.54. The stock has a fifty day moving average of $6.43 and a two-hundred day moving average of $10.48. The firm has a market capitalization of $226.64 million and a P/E ratio of -4.82. Stealth BioTherapeutics has a one year low of $4.97 and a one year high of $20.99.
Several equities analysts have recently commented on the company. Zacks Investment Research raised Stealth BioTherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Nomura set a $28.00 target price on Stealth BioTherapeutics and gave the company a “buy” rating in a research report on Friday, October 18th. Jefferies Financial Group set a $9.00 target price on Stealth BioTherapeutics and gave the company a “hold” rating in a research report on Tuesday, October 15th. HC Wainwright set a $21.00 target price on Stealth BioTherapeutics and gave the company a “buy” rating in a research report on Friday, October 18th. Finally, Cantor Fitzgerald assumed coverage on Stealth BioTherapeutics in a research report on Friday, September 27th. They issued an “overweight” rating and a $18.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Stealth BioTherapeutics presently has a consensus rating of “Buy” and an average price target of $21.86.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Featured Article: Convertible Shares
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.